TrialNet Staff

Jason Gaglia, MD, MMSc

Principal Investigator

Jason Gaglia is an Assistant Investigator and attending adult Endocrinologist at Joslin Diabetes Center and is a faculty member at Harvard Medical School. He holds undergraduate degrees in Biology, Chemistry, Biochemistry, and Physics from Rutgers College. He is a graduate of the Harvard-MIT Health Sciences and Technology program at Harvard Medical School and the Beth Israel Deaconess-Harvard Clinical Investigator Training Program. Dr. Gaglia is a former member of the clinical islet transplant team at the National Institutes of Health. Dr. Gaglia is an expert in endocrine-related imaging, leading several clinical trials in this area. His current research focuses on developing clinically applicable measures of inflammation and beta-cell mass, keys to furthering our understanding of diabetes. As a practicing Endocrinologist, he sees patients at Joslin Clinic and Harvard Vanguard Medical Associates.

Sarah Szubowicz, MPH

Study Coordinator

Sarah is a graduate of the University of Connecticut where she earned a BS in Molecular and Cell Biology. She went on to earn a Master's in Public Health from Tulane University School of Public Health and Tropical Medicine in New Orleans in 2011. Sarah has been an active member of the TrialNet team since October 2011 and hopes to eventually become a Physician's Assistant.

Ronald Benjamin

Research Assistant

Ronald Benjamin is a graduate of York College of the City University of New York where he earned a BS in Chemistry. He went on to earn a Master's in Public Affairs and International Relations from the University of Massachusetts Boston in 2011. Ronald has been an active member of the TrialNet team since November 2012 and hopes to become a Physician.

Gordon Weir, MD

Co-Investigator

Dr. Weir is Co-Head of the Section on Islet Cell Biology and Regenerative Medicine and holds the Diabetes Research and Wellness Foundation Chair at Joslin, and is also Professor of Medicine at Harvard Medical School. His research interests focus on pancreatic islets and what goes wrong in diabetes. He is also leading an NIH clinical trial testing a new therapeutic approach to slowing the progression of new-onset type 1 diabetes.

Richard Jackson, MD

Co-Investigator

Richard Jackson is a Senior Physician at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Ohio State University School of Medicine with fellowship training in Endocrinology at Duke.

Dr. Jackson is one of the investigators responsible for the use of autoantibodies as tools for risk assessment in type 1 diabetes. His efforts led to the launch of the Diabetes Prevention Trial - Type 1 (DPT-1), the first National Institutes of Health-sponsored clinical study of the effectiveness of preventive strategies in first- and second-degree relatives of patients with type 1 diabetes and the predecessor to what is today Type 1 Diabetes TrialNet.

Dr. Jackson launched the Joslin Diabetes Outpatient Intensive Treatment (DO IT) program. With the U.S. Department of Agriculture's Cooperative State, Research, Education and Extension Service, Dr. Jackson has set up a series of community-based programs, mostly in underserved rural locations, to provide self-care information, blood pressure screenings and blood tests. He sees patients at Joslin Clinic.

Alyne Ricker, MD

Co-Investigator

Alyne Ricker is a pediatric Endocrinologist at Joslin Diabetes Center and faculty member at Harvard Medical School. She is a graduate of Notre Dame. She received her medical degree from University of Geneva, Switzerland with fellowship training at Calgary University, Boston Children's Hospital, and Joslin Diabetes Center. She sees patients at Joslin Clinic.